NCT03409146

Brief Summary

Accuracy and Reliability of the Novii device (fetal heart rate, maternal heart rate and uterine activity) compared with Food and Drug Administration (FDA) approved techniques

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 28, 2014

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 13, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 13, 2017

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

January 11, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

January 24, 2018

Completed
Last Updated

February 9, 2021

Status Verified

February 1, 2021

Enrollment Period

2.7 years

First QC Date

January 11, 2018

Last Update Submit

February 4, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Fetal Heart Rate (FHR) Positive Percentage Agreement (PPA)

    PPA(%)=(a/(a+C))x100, where "a" represents the number of 2 second epochs when the Novii FHR is within +/-10% of the predicate device FHR for each 2 second epoch, and "c" are the number of 2 second epochs when the Novii FHR is not within +/- 10% of the predicate device FHR or is absent.

    through study completion, an average of 1 year

Secondary Outcomes (5)

  • Mean Percentage FHR Equivalence

    through study completion, an average of 1 year

  • Uterine Activity (UA) Sensitivity (from Individual Contractions)

    through study completion, an average of 1 year

  • Uterine activity Positive Percentage Agreement (from Interpretable Data)

    through study completion, an average of 1 year

  • Maternal Heart Rate (MHR) Positive Percentage Agreement (PPA)

    through study completion, an average of 1 year

  • Mean Percentage MHR Equivalence

    through study completion, an average of 1 year

Study Arms (1)

Term Patients

Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton \>37 week pregnancy. Subjects will be recruited for the study in the following groups : At least 10 patients with Body Mass Index (BMI) \< 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2

Device: Monica Novii Wireless Patch System

Interventions

The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.

Term Patients

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant women at term
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Pregnant Women at Term

You may qualify if:

  • She has a term or near term (≥36 completed weeks) singleton gestation in a cephalic presentation and has been admitted to the Labor and Delivery Unit .
  • She is in the latent phase of spontaneous labor, or has been admitted for induction of labor.
  • She has given her informed consent to participate as a subject.

You may not qualify if:

  • Known major fetal malformation or chromosome abnormality.
  • Multiple gestation
  • A condition for which cesarean will likely be carried out shortly.
  • Subject plans not to have electronic fetal monitoring.
  • Involvement in another clinical trial currently or previously in this pregnancy that, in the investigator's opinion, would affect the conduct of this study.
  • Medical or obstetric problem that would preclude the use of abdominal electrodes (e.g., skin eruptions, history of sensitivity to adhesives).
  • Parturient is under age 18.
  • Medical or obstetric problem that in investigator's opinion would make the patient incapable of taking part in the study.
  • Inability to understand the consent information due to medical illness or diminished intellectual capacity, or insurmountable language barrier.
  • Potential for coercion, e.g. Medical Center employees, prisoners.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Arizona Medical Center

Tucson, Arizona, 85724, United States

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 11, 2018

First Posted

January 24, 2018

Study Start

May 28, 2014

Primary Completion

February 13, 2017

Study Completion

February 13, 2017

Last Updated

February 9, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Locations